BR112012007979A2 - moduladores de gpr40 de pirrolidina - Google Patents

moduladores de gpr40 de pirrolidina

Info

Publication number
BR112012007979A2
BR112012007979A2 BR112012007979A BR112012007979A BR112012007979A2 BR 112012007979 A2 BR112012007979 A2 BR 112012007979A2 BR 112012007979 A BR112012007979 A BR 112012007979A BR 112012007979 A BR112012007979 A BR 112012007979A BR 112012007979 A2 BR112012007979 A2 BR 112012007979A2
Authority
BR
Brazil
Prior art keywords
gpr40 modulators
pyrrolidine
modulators
pyrrolidine gpr40
compounds
Prior art date
Application number
BR112012007979A
Other languages
English (en)
Inventor
Bruce A Ellsworth
Elizabeth A Jurica
William R Ewing
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112012007979A2 publication Critical patent/BR112012007979A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

moduladores de gpr40 de pirrolidina a presente de invenção refere-se a compostos de fórmula (i): ou um estereoisônero, ou um sal farmaceuticamente aceitável dos mesmos , em que todas as variáveis são como aqui definidas. estes compostos são moduladores do receptor acoplado a proteína ggpr40 que podem ser usados como medicamentos.
BR112012007979A 2009-10-06 2010-10-05 moduladores de gpr40 de pirrolidina BR112012007979A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24889609P 2009-10-06 2009-10-06
PCT/US2010/051389 WO2011044073A1 (en) 2009-10-06 2010-10-05 Pyrrolidine gpr40 modulators

Publications (1)

Publication Number Publication Date
BR112012007979A2 true BR112012007979A2 (pt) 2016-03-29

Family

ID=43242297

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007979A BR112012007979A2 (pt) 2009-10-06 2010-10-05 moduladores de gpr40 de pirrolidina

Country Status (13)

Country Link
US (1) US8288404B2 (pt)
EP (1) EP2486005B1 (pt)
JP (1) JP2013506714A (pt)
KR (1) KR20120104534A (pt)
CN (1) CN102639495A (pt)
AR (1) AR078542A1 (pt)
AU (1) AU2010303670A1 (pt)
BR (1) BR112012007979A2 (pt)
CA (1) CA2777041A1 (pt)
MX (1) MX2012003389A (pt)
RU (1) RU2012118504A (pt)
TW (1) TW201116510A (pt)
WO (1) WO2011044073A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818993A1 (en) 2010-11-24 2012-05-31 Allergan, Inc. Modulators of s1p receptors
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
EA201590951A1 (ru) 2012-11-16 2015-08-31 Бристол-Майерс Сквибб Компани Дигидропиразольные модуляторы gpr40
KR20150082615A (ko) 2012-11-16 2015-07-15 브리스톨-마이어스 스큅 컴퍼니 피롤리딘 gpr40 조절제
SG11201503562PA (en) * 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
HUE032401T2 (en) 2012-11-16 2017-09-28 Bristol Myers Squibb Co Dihydropyrazole GPR40 modulators
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
AU2014300629A1 (en) 2013-06-24 2015-12-24 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
KR101824346B1 (ko) 2013-12-13 2018-01-31 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
BR112016025188A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
WO2015171757A1 (en) * 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
DK3140296T3 (en) 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
WO2018095344A1 (en) * 2016-11-24 2018-05-31 Shanghai Meton Pharmaceutical Co., Ltd Isocitrate dehydrogenase (idh) inhibitor
CA3091015C (en) 2018-02-13 2023-02-21 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
CN111253223A (zh) * 2020-03-20 2020-06-09 重庆医科大学 一类大位阻三芳基甲烷衍生物及其合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10309929B4 (de) * 2003-03-07 2006-02-23 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators

Also Published As

Publication number Publication date
US8288404B2 (en) 2012-10-16
CA2777041A1 (en) 2011-04-14
JP2013506714A (ja) 2013-02-28
US20110082165A1 (en) 2011-04-07
CN102639495A (zh) 2012-08-15
EP2486005A1 (en) 2012-08-15
EP2486005B1 (en) 2014-06-18
KR20120104534A (ko) 2012-09-21
MX2012003389A (es) 2012-04-10
AU2010303670A1 (en) 2012-03-29
WO2011044073A1 (en) 2011-04-14
RU2012118504A (ru) 2013-11-20
TW201116510A (en) 2011-05-16
AR078542A1 (es) 2011-11-16

Similar Documents

Publication Publication Date Title
BR112012007979A2 (pt) moduladores de gpr40 de pirrolidina
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112015011031A2 (pt) moduladores de grp40 de di-hidropirazol
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112015021596A2 (pt) moduladores de gpr120 de ácido oxabiciclo[2.2.2]
JO3297B1 (ar) تركيبات و طرق لتعديل fxr
CA2797033C (en) Highly active polypeptides and methods of making and using the same
BR112012026950A2 (pt) composto, e, uso de um composto
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
BR112014010576A2 (pt) inibidores de neprilisina
BR112014018027A8 (pt) Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
BR112015021386A2 (pt) moduladores de ácido biciclo [2.2.2] gpr120
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
BR112014013228A2 (pt) arila di-hidropiridinona e piperidinona como inibidores de mgat2
EA201290416A1 (ru) Новые спиропиперидиновые соединения
BR112015021990A2 (pt) moduladores de gpr120 de ácido biciclo [2.2.1]
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
BR112012025590A2 (pt) análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
BRPI1014802B8 (pt) profármacos de triptolida.
BR112015029598A2 (pt) inibidores de di-hidropiridinona mgat2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]